Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer

Lung Cancer

Volumn 77, Issue 3, 2012, Pages 593-599

  Hu, Jing ^a   Liu, Yan Long ^a   Piao, Song Lin ^b   Yang, Dong Dong ^a   Yang, Yan Mei ^a   Cai, Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

BMI 1; Non small cell lung cancer; Oncogene; P AKT; Prognosis; PTEN; USP22

Indexed keywords

BMI1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UBIQUITIN THIOLESTERASE; UBIQUITIN THIOLESTERASE 22; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONCOGENES; PHENOTYPE; POLYCOMB REPRESSIVE COMPLEX 1; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; THIOLESTER HYDROLASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84865264616     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.05.112     Document Type: Article

References (34)

1. Global patterns of cancer incidence mortality rates trends. Cancer Epidemiol Biomarkers Prev 2010, 19(8):1893-1907.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55(March-April (2)):74-108.
3. Tyczynski J.E., Bray F., Parkin D.M. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol 2003, 4(January (1)):45-55.
4. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3(August (8)):819-831.
5. Toh C.K. The changing epidemiology of lung cancer. Methods Mol Biol 2009, 472:397-411.
6. Jett J.R., Schild S.E., Keith R.L., Kesler K.A. American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:266S-276S.
7. Robinson L.A., Ruckdeschel J.C., Wagner H., Stevens C.W. American College of Chest Physicians Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(September (3 Suppl.)):243S-265S.
8. O'Rourke N., Roqué I., Figuls M., Farré Bernadó N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010, June (6):CD002140.
9. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22(January (2)):330-353.
10. Anderson C.S., Curran W.J. Combined modality therapy for stage III non-small-cell lung cancer. Semin Radiat Oncol 2010, 20(July (3)):186-191.
11. Price K.A., Azzoli C.G., Gaspar L.E. Chemoradiation for unresectable stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2008, 20(Fall (3)):204-209.
12. Ramalingam S.S., Owonikoko T.K., Khuri F.R. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011, 61(March-April (2)):91-112.
13. Glinsky G.V., Berezovska O., Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115(6):1503-1521.
14. Glinsky G.V. " Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 2008, 26(17):2846-2853.
15. Glinsky G.V. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 2006, 5(11):1208-1216.
16. Lahad J.P., Mills G.B., Coombes K.R. Stem cell-ness: a " magic marker" for cancer. J Clin Invest 2005, 115(June (6)):1463-1467.
17. Liu Y.L., Yang Y.M., Xu H., Dong X.S. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol 2010, 25(November (11)):1800-1805.
18. Liu Y.L., Yang Y.M., Xu H., Dong X.S. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol 2011, 103(March (3)):283-289.
19. Yang D.D., Cui B.B., Sun L.Y., Zheng H.Q., Huang Q., Tong J.X., et al. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys 2011, 61(December (3)):703-710.
20. Zhang Y., Yao L., Zhang X., Ji H., Wang L., Sun S., et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 2011, 137(August (8)):1245-1253.
21. Lv L., Xiao X.Y., Gu Z.H., Zeng F.Q., Huang L.Q., Jiang G.S. Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem 2011, 346(January (1-2)):11-21.
22. Liu Y.L., Jiang S.X., Yang Y.M., Xu H., Liu J.L., Wang X.S. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys 2012, 62(January (1)):229-235.
23. Zhang X.Y., Varthi M., Sykes S.M., Phillips C., Warzecha C., Zhu W., et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 2008, 29(January (1)):102-111.
24. Zhang X.W., Sheng Y.P., Li Q., Qin W., Lu Y.W., Cheng Y.F., et al. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 2010, February (9):40.
25. Noguchi M. Stepwise progression of pulmonary adenocarcinoma - clinical and molecular implications. Cancer Metastasis Rev 2010, 29(March (1)):15-21.
26. Nacht M., Dracheva T., Gao Y., Fujii T., Chen Y., Player A., et al. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci USA 2001, 98(December (26)):15203-15208.
27. Hayes D.N., Monti S., Parmigiani G., et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006, 24:5079-5090.
28. Hayes D.N., Monti S., Parmigiani G., Gilks C.B., Naoki K., Bhattacharjee A., et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006, 24(November (31)):5079-5090.
29. Guo L., Ma Y., Ward R., Castranova V., Shi X., Qian Y. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 2006, 12(June (11 Pt 1)):3344-3354.
30. Liu S., Dontu G., Mantle I.D., Patel S., Ahn N.S., Jackson K.W., et al. Hedgehog signaling and BMI-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006, 66(June (12)):6063-6071.
31. Lessard J., Sauvageau G. BMI-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423(May (6937)):255-260.
32. Park I.K., Qian D., Kiel M., Becker M.W., Pihalja M., Weissman I.L., et al. BMI-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423(May (6937)):302-305.
33. Molofsky A.V., Pardal R., Iwashita T., Park I.K., Clarke M.F., Morrison S.J. BMI-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003, 425(October (6961)):962-967.
34. Glinsky G.V. Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem Cell Rev 2007, 3(January (1)):79-93.